ABL1 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

AFF1 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains AFF1 status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ALK is an inclusion eligibility criterion in 3 clinical trials for neuroblastoma, of which 2 are open and 1 is closed. Of the trials that contain ALK status and neuroblastoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].

ARAF is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ATM is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ATR is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BCR is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains BCR status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

BRAF is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CRKL is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

DEK is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains DEK status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

EGFR is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains EGFR status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains ELL status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB4 status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCA is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCB is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCC is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCE is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCF is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCG is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCI is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCL is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCM is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

HRAS is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

KMT2A is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2A status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KRAS is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MECOM is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT1 status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT10 status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT3 status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT4 status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYC is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCN is an inclusion eligibility criterion in 20 clinical trials for neuroblastoma, of which 16 are open and 4 are closed. Of the trials that contain MYCN status and neuroblastoma as inclusion criteria, 6 are phase 1 (4 open), 3 are phase 1/phase 2 (3 open), 4 are phase 2 (4 open), 3 are phase 3 (3 open), and 4 are no phase specified (2 open) [3].

NBN is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NF1 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRAS is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains NRIP3 status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NUP214 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains NUP214 status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PTEN is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51D is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD54L is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains RPN1 status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SRC is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains SRC status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TP53 is an inclusion eligibility criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].